AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...

Nara Smith shared pictures of her recent eczema flare-ups on Instagram, where the model got candid about her journey with the ...

Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...

Being a social media star may seem like the high life but Nara Smith, fashion model-turned-TikTok creator just pulled back the curtain on all that appears glitz and glam by getting candid about her ...

AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

It's still early science -- studies in mice and in human cells -- but researchers are on the trail of an effective n ...

Nara Smith, known for her picture-perfect content, has opened up about her health challenges, saying it inspired her to start ...

The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study p ...

UK MHRA grants marketing authorization to Leo Pharma’s delgocitinib to treat adult patients with moderate to severe chronic hand eczema: United Kingdom Thursday, December 12, 20 ...